Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Clinical Studies and Therapies in Parkinson's Disease

Translations from Preclinical Models
TaschenbuchKartoniert, Paperback
Englisch
Elsevier Science & Technologyerschienen am16.06.2021
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4-6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson's disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book's discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.mehr
Verfügbare Formate
TaschenbuchKartoniert, Paperback
EUR145,50
E-BookEPUBDRM AdobeE-Book
EUR131,00

Produkt

KlappentextMore than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4-6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson's disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book's discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.
Details
ISBN/GTIN978-0-12-822120-4
ProduktartTaschenbuch
EinbandartKartoniert, Paperback
Erscheinungsjahr2021
Erscheinungsdatum16.06.2021
SpracheEnglisch
Gewicht504 g
Artikel-Nr.57992752

Inhalt/Kritik

Inhaltsverzeichnis
1. Parkinson's disease2. Parkinsons pharmacological therapy3. Dopamine synthesis4. Dopamine storage and release5. Dopamine oxidative deamination6. Dopamine methylation7. Dopamine oxidation to neuromelanin and neurotoxic metabolites8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity9. Preclinical model based on exogenous neurotoxins for Parkinson's disease10. Preclinical models based on genetic mutations associated with the familial form of Parkinsons disease11. Preclinical models based on endogenous neurotoxins12. Conclusionsmehr

Autor

Dr. Juan Segura-Aguilar, PhD, is a professor of molecular and clinical pharmacology at the University of Chile, Santiago, Chile. He obtained his PhD in biochemistry from Stockholm University, Stockholm, Sweden in 1989. He was previously an associate professor at Uppsala University, Uppsala, Sweden. In 1998, he began as an associate professor at University of Chile, and since 2001 has been a full professor. His research has been focused on mechanisms involved in dopaminergic neuron degeneration in Parkinson´s disease. He has more than 140 publications of his research work on neurodegenerative disorders.
Weitere Artikel von
Segura-Aguilar, Juan